(Q54334284)

English

Susceptibility of autologous target cells to lysis by lymphokine-activated effectors from interferon-alpha-treated chronic myelogenous leukaemia patients.

scientific article published in January 1990

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/2289210

Susceptibility of autologous target cells to lysis by lymphokine-activated effectors from interferon-alpha-treated chronic myelogenous leukaemia patients. (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/2289210

1 reference

based on heuristic

inferred from title

Gerhard Ehninger

2

object named as

G Ehninger

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/2289210

author name string

G Pawelec

1

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/2289210

H Schmidt

3

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/2289210

C Müller

4

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/2289210

H J Bühring

5

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/2289210

M Reutter

6

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/2289210

F W Busch

7

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/2289210

publication date

1 January 1990

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/2289210

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/2289210

32

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/2289210

3

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/2289210

167-172

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/2289210

NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.

1 reference

https://api.crossref.org/works/10.1007%2FBF01771452

21 January 2018

Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of human granulocyte-macrophage colony-stimulating factor using a sensitive immunoassay

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lysis of fresh leukemic blasts by interferon-activated human natural killer cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects of recombinant interleukin 2-activated natural killer cells on autologous peripheral blood hematopoietic progenitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Indications for marrow transplantation in chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum-free medium for generation and propagation of functional human cytotoxic and helper T cell clones

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synthesis of granulocyte colony-stimulating factor and its requirement for terminal divisions in chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Refractoriness to α-interferon (Intron A) in previously chemotherapy-treated patients with chronic myelocytic leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunophenotype of blast cells in chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Resistance of some leukemic blasts to lysis by lymphokine activated killer (LAK) cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activity in vitro in chronic myelogenous leukaemia revealed after treating peripheral cells with cytosine arabinoside

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytokine-induced enhancement of the susceptibility of hairy cell leukaemia lymphocytes to natural killer cell lysis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphokine activated killing of fresh human leukaemias

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphokine-activated killer cells selectively kill tumor cells in bone marrow without compromising bone marrow stem cell function in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elimination by interferon-alpha of malignant clone in chronic myeloid leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clonally restricted natural killer-like cytotoxicity displayed by cloned human T cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Studies of the proliferation and differentiation of immature myeloid cells in vitro. I. Chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Short-term culture of acute myeloid leukemia blasts: analysis of acquired susceptibility to activated natural killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I study of interleukin-2 in children with cancer and evaluation of clinical and immunologic status during therapy. A Pediatric Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of CD3 antibodies on cytotoxicity against leukemic cells resistant to activated killer cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of chronic myelogenous leukemia: chemotherapy and interferons

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of human monocyte susceptibility to lymphokine-activated killer cell lysis by granulocyte-macrophage colony-stimulating factor.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphokine-activated killer cell purging of leukemia cells from bone marrow prior to syngeneic transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukaemia after in vivo treatment with interferon-alpha (Wellferon).

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pretreatment of chronic myelogenous leukemic blood samples with cytosine arabinoside prior to mixed lymphocyte culture typing

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Generation and characterization of IL-2-activated bone marrow cells as a potent graft vs tumor effector in transplantation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF01771452

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/2289210

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/2289210

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54334284&oldid=2212428180"